Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. - Wikidata - awgldk - TriplyDB

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33988701

about

The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide Alzheimer mechanisms and therapeutic strategies Retinoids for treatment of Alzheimer's disease Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial Diverse molecular targets for therapeutic strategies in Alzheimer's disease γ-Secretase inhibitors and modulators.Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease Potential use of γ-secretase modulators in the treatment of Alzheimer disease A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets.Preventing Alzheimer's disease by means of natural selection β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice Are we prepared to deal with the Alzheimer's disease pandemic?Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.Combination therapy in a transgenic model of Alzheimer's disease.LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Sample size determination in group-sequential clinical trials with two co-primary endpoints.Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Why pleiotropic interventions are needed for Alzheimer's disease.A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial The secretases: enzymes with therapeutic potential in Alzheimer disease.The Alzheimer's disease mitochondrial cascade hypothesis Presenilin/gamma-Secretase and Inflammation.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials NSAIDs may protect against age-related brain atrophy.Current and emerging drug treatment options for Alzheimer's disease: a systematic review.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications.

P2860

Q21090025-203A730B-BD11-48AD-AF05-F9F2AA43B360 Q22252311-D3F56613-4CED-40DB-8925-3D09A5542026 Q22252919-1891518A-584C-4381-A156-52AA4B24E97D Q24203739-479BEDC2-BF83-4BC1-BB8C-9960887522C1 Q24298408-DAC570E6-3D9A-42B7-871A-904BEFCEBECE Q24607545-0B72E039-2169-47E3-8C01-A5A4A3C22FBD Q26827193-64EEF1C5-1197-40C2-94A0-795E786CE442 Q26830462-44B60501-8AFD-494B-A416-7CA5A453DCAE Q26860246-475F71E0-2860-44DF-825A-0B186DDAEFD3 Q26866006-F0919EBD-AB70-48F2-93BE-B482E4A11C35 Q27003841-EEE0EFC5-0F7D-4D61-BCE9-DBBD4D964D1E Q27004876-D5ECD240-9042-4DD0-A335-062C4E8E3E94 Q27311651-77121C07-C465-4BD5-8BC7-240D82A603CB Q27316634-030F6CAE-8AF1-4B30-A34B-E6311D3BAA83 Q27324311-9989197A-973B-473B-86B5-0F80ECD586B3 Q27345159-B244095A-511D-4944-8C6B-045C43588E41 Q28088701-A71E5894-0C12-4EB7-BC82-AF7378BB15E4 Q28245473-864A7895-3643-4419-A89C-4BACCDB3FB44 Q28651801-D0152AE7-2332-4D43-A606-FB57EE38683F Q30392542-F7D07284-D1F5-45BB-A0EB-B44AC941DC7D Q30513293-5A0CE3EF-078D-48A6-9953-F6B70E6A0B4E Q30616078-CD60FBB2-95F9-4655-AFAF-EF5C172C8B57 Q30676660-67D6378B-DC4C-4A86-B966-2BDC575DB6E9 Q30831806-347B7BC9-035C-44F2-BDE4-BF8748B57679 Q33745617-2EB582D3-A595-47A8-BAA3-48C0919AD95E Q33783000-6481FC2A-14FA-4C4E-A6CB-903C058ABDCD Q33848180-8504D846-7BD5-42D0-985A-A1BB227CBC81 Q33851241-09991B2A-A927-4C57-9909-1A0C8015B612 Q33876128-0C886F9A-985A-4D15-91D2-3DF37332B8FB Q33880702-02B4624A-4403-4666-8B4C-862D388CB17B Q33887222-95C995F2-91D9-400C-8420-F1C77517FF26 Q33905871-14AD6FDC-9C6A-4C61-9329-495CF2911334 Q33918695-A5776B3C-A709-4375-ABD4-DAD5B0FA22DE Q34014237-B3D2DEBF-8862-4453-B2BD-C0345E3B481A Q34151315-6CE47D0D-9E43-4009-902C-D61C05231AEE Q34222721-E04EA6A8-C7DE-4A64-9A19-45F85F1BDD50 Q34376103-ADCB0007-A361-48FE-9E86-D7C13A5CBCA2 Q34382868-6024B763-4F60-4B01-BDA1-6703FA4D72B2 Q34408888-DC129892-5F65-4580-9D2D-B00446559578 Q34412322-D6218701-FE47-43FA-91FC-6BAD331B6513

P2860

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

http://www.wikidata.org/entity/Q33988701

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@ast

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@en

type

label

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@ast

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@en

prefLabel

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@ast

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@en

P1433

Q33988701-DDB0CB2B-D58B-4DEB-8527-2E43BB309952

P1476

Q33988701-456A5D3A-DCAC-4B9E-BE73-ED89F5602CF5

P2093

Q33988701-507DC2B1-D6E9-468F-9D15-331016CF1CE6

Q33988701-7CAD493A-540B-41F0-869E-5320B06F5479

Q33988701-8E5BDB81-867D-4280-A846-4F579C9DCD03

Q33988701-A274A8DF-3A4F-4F4B-874F-578F93D43FEE

Q33988701-ADB9CEAE-D015-47FD-A0C5-1027920D6193

Q33988701-B412DA6D-0A64-4B9E-831E-46742C493A24

Q33988701-B53A022D-4BB3-47EB-8F25-71C2CA8EC772

P2860

Q33988701-0414C980-9AB5-49DC-970D-223868BB34D8

Q33988701-0812CA1B-F99F-4DBD-9DF6-D2D89F2023E3

Q33988701-090BC2A6-C988-4184-9DAF-A3E3B5497987

Q33988701-14C99D80-BE9B-4B18-A7A5-D8EB772997F8

Q33988701-1ED04304-4202-44E6-9136-BF5E0542803A

Q33988701-1F36CE40-CB13-4E6C-BCDA-493C6A257632

Q33988701-2E75357D-E7B5-4A88-8ECF-A35BADC3342D

Q33988701-30058737-98B8-474A-BCCA-9D2BE0498D9A

Q33988701-46E5D723-94F1-4F52-B819-7E35B7A663CC

Q33988701-48BCEAC5-7945-4FCE-8E0C-FEEA31D5B875

P304

Q33988701-B6AE398F-A093-44D5-816C-11A90DF2ED20

P31

Q33988701-ECC84029-7335-40BB-935B-AFB9F802338B

P356

Q33988701-F64D8FEF-68A5-45C9-B46B-E773E7BF1DED

P407

Q33988701-5C39A0C0-8A40-460F-922D-97593F2A94F9

P433

Q33988701-5F761AA2-0E51-471C-BF6C-507323261037

P478

Q33988701-8E00BEFA-8ED2-46F6-A62D-C6608F958B1F

P50

Q33988701-85262525-0CA4-4F38-89DA-6B1AB62E2128

P577

Q33988701-73823603-C4C8-45B9-8A95-4BBDEF563805

P5875

Q33988701-0900AB53-8531-4DA0-B7CF-16F852CCE08F

P698

Q33988701-C9E8D1C4-52A0-47DB-99A7-F0278E5C4D8B

P921

Q33988701-CF585B27-005E-47CF-84B7-9BC867DD3886

P932

Q33988701-AE33DA99-24CC-499B-A31B-FD9FACA6820B

P356

P1433

Journal of the American Medical Association

P1476

Effect of tarenflurbil on cogn ...... a randomized controlled trial.

@en

P2093

Andrew P Beelen

http://www.w3.org/2001/XMLSchema#string

David A Amato

http://www.w3.org/2001/XMLSchema#string

Edward A Swabb

http://www.w3.org/2001/XMLSchema#string

Gordon Wilcock

http://www.w3.org/2001/XMLSchema#string

Kenton H Zavitz

http://www.w3.org/2001/XMLSchema#string

Lon S Schneider

http://www.w3.org/2001/XMLSchema#string

Tarenflurbil Phase 3 Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Alzheimer's disease: genes, proteins, and therapy

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

Alzheimer's disease: the amyloid cascade hypothesis

The Clinical Dementia Rating (CDR): current version and scoring rules

Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

P304

2557-2564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2009.1866

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

302

http://www.w3.org/2001/XMLSchema#string

P50

Robert C. Green

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40686771

http://www.w3.org/2001/XMLSchema#string

P698

20009055

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2902875

http://www.w3.org/2001/XMLSchema#string